Amoeba Sa · EURONEXT:ALMIB
Amoeba Sa — Shareholder Meeting (June 2025)
20 slides from Amoeba Sa's shareholder meeting presentation, Jun 26, 2025
Slide 1: General Meeting June 26 2025
GENERAL MEETING JUNE,26 2025
Slide 2: Presentation of the General Meeting
26 June 2025 | Presentation of the General Meeting
Slide 3: Amoéba Chronology
Introduction Development Biocontrol Cosmetics Finance Conclusion AMOÉBA CHRONOLOGY From an R&D company to a Commercialization company Creation of Amoéba 2010 13 years of R&D to become the only company in the world capable of producing amoeba on an industrial scale Initial public offering 2015 Eurone
Slide 4: A Technological Platform with Multiple Applications
Introduction Development Biocontrol Cosmetics Finance Conclusion A TECHNOLOGICAL PLATFORM WITH MULTIPLE APPLICATIONS 2 pre-marketing ranges Biocontrol Cosmetics Crop treatment Cosmetics ingredient Natural alternative to chemical plant Skin care and Well-Aging ingredients protection products INCI lis
Slide 5: We Will Be Soon Ready to Play Grand Slam
Introduction Development Biocontrol Cosmetics Finance Conclusion WE WILL BE SOON READY TO PLAY GRAND SLAM Projected timetable for approval on main areas Coming soon… S1-2022 S2-2022 S1-2023 S2-2023 S1-2024 S2-2024 S1-2025 S2-2025 S1-2026 Recommendation of active substance Peer-review by Approval of
Slide 6: Axpera
Introduction Development Biocontrol Cosmetics Finance Conclusion AXPERA Our range of solutions for the transition from chemical to organic production Positive impact on agriculture Market launch for 2025-2026 Regulatory A highly competitive level of performance, Positive and definitive conclusions o
Slide 7: Final Approval by the European Commission
Introduction Development Biocontrol Cosmetics Finance Conclusion FINAL APPROVAL BY THE EUROPEAN COMMISSION A determining milestone is now completed What are the key points about our active substance? ✓ Proven fungicidal efficacy; ✓ A low-risk profile for human and animal health, as well as for ecosy
Slide 8: Amoeba x Koppert (1/2)
Introduction Development Biocontrol Cosmetics Finance Conclusion AMOEBA x KOPPERT (1/2) Signature of a major distribution agreement with a world leader in biocontrol The start of a collaboration with Why partner together ? a world leader in biocontrol ✓ Mutual expertise: Koppert, a global leader in
Slide 9: Amoeba x Koppert (2/2)
Introduction Development Biocontrol Cosmetics Finance Conclusion AMOEBA x KOPPERT (2/2) A new milestone for Amoéba Exclusive distribution rights for Koppert during a period of 5 years Vines and vegetable crops in greenhouses and open fields 18 European countries (France, the Netherlands, Germany, It
Slide 10: And We Have a Potential Game-Changer…
Introduction Development Biocontrol Cosmetics Finance Conclusion AND WE HAVE A POTENTIAL GAME-CHANGER… Short-term development: An additional market segment to optimise the Launch of a biofertiliser innovation use of industrial equipment Promising initial results : 1kg of active substance = 5 liters
Slide 11: The Potential of Biocontrol Has Only Just Begun to Be Exploited
Introduction Development Biocontrol Cosmetics Finance Conclusion THE POTENTIAL OF BIOCONTROL HAS ONLY JUST BEGUN TO BE EXPLOITED Agreement with Koppert: Vines and vegetable crops, across 18 European countries and the US June 2025 Coming soon… Discussions engaged with Koppert and other actors Crops (
Slide 12: Skin Protection (Anti-ageing / Anti-UV)
Introduction Development Biocontrol Cosmetics Finance Conclusion SKIN PROTECTION (ANTI-AGEING / ANTI-UV) A recent and promising innovation with proven effects October 2023 - Remarkable in-vitro studies Anti-ageing effect Visible restoration of skin structure Anti-UV effect Young skin irradiated Youn
Slide 13: Skin Protection (Anti-ageing / Anti-UV)
Introduction Development Biocontrol Cosmetics Finance Conclusion SKIN PROTECTION (ANTI-AGEING / ANTI-UV) A recent and promising innovation with proven effects May 2024 – the clinical study Wrinkle reduction after 28 days confirms excellent in-vitro tests Results of clinical trials justifying very st
Slide 14: Skin Protection (Anti-ageing / Anti-UV)
Introduction Development Biocontrol Cosmetics Finance Conclusion SKIN PROTECTION (ANTI-AGEING / ANTI-UV) A recent and promising innovation with proven effects 2023 2024 2025 2025-26 2026-27 Brevet INCI Label Cosmos Development Production & Filing of a patent to Inclusion of our cosmetic approved • B
Slide 15: Amoéba x Oriental Beauty Valley
Introduction Development Biocontrol Cosmetics Finance Conclusion AMOÉBA x ORIENTAL BEAUTY VALLEY Signature of a Memorandum of Understanding with Metron Technology, a subsidiary of China's leading cosmetics company A strategic player in cosmetics in Two major objectives China ✓ On the regulatory fron
Slide 16: A Major Reinforcement for the Amoéba Board
Introduction Development Biocontrol Cosmetics Finance Conclusion A MAJOR REINFORCEMENT FOR THE AMOÉBA BOARD A personality with multiple areas of expertise in the cosmetics and beauty industry Charlotte FRANCERIES A major player in the world of cosmetics and communication ✓ 25 years with the L'Oréal
Slide 17: Why Invest …
Introduction Development Biocontrol Cosmetics Finance Conclusion WHY INVEST … The only company in the world dedicated to amoeba culture Unique Technological Expertise Leadership Position ✓ The only company capable of cultivating an amoeba on ✓ Competitive advantages driven by unique specialization a
Slide 18: … Now
Introduction Development Biocontrol Cosmetics Finance Conclusion … NOW Financial markets rediscover Amoéba +133% Amoéba share price from June 2024 to June 2025 Positive share price trend over last 12 months +263% Positive liquidity Evolution 6 months 2025 vs H2 2024 €53m Market capitalisation 30/06/
Slide 19: Amoéba contact
Amoéba amoeba-nature.com amoeba@actus.fr
Slide 20: Disclaimer
DISCLAIMER References herein to this presentation (the “Presentation”) shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the “Company”), any question-and-answer session following that oral presentation and any further information that may b